Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Receivables - Net (2023 - 2025)

Historic Receivables - Net for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $66.8 million.

  • Iovance Biotherapeutics' Receivables - Net rose 1971.2% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year increase of 1971.2%. This contributed to the annual value of $69.3 million for FY2024, which is 4582052.98% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Receivables - Net stood at $66.8 million for Q3 2025, which was up 1971.2% from $59.9 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Receivables - Net high stood at $70.9 million for Q1 2025, and its period low was $33000.0 during Q2 2023.
  • Moreover, its 3-year median value for Receivables - Net was $55.8 million (2024), whereas its average is $39.4 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Receivables - Net surged by 9566969.7% in 2024 and then surged by 1971.2% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Receivables - Net stood at $151000.0 in 2023, then soared by 45820.53% to $69.3 million in 2024, then fell by 3.72% to $66.8 million in 2025.
  • Its last three reported values are $66.8 million in Q3 2025, $59.9 million for Q2 2025, and $70.9 million during Q1 2025.